These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22077076)

  • 21. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 22. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.
    Steinbrook R
    N Engl J Med; 2006 Oct; 355(14):1409-12. PubMed ID: 17021315
    [No Abstract]   [Full Text] [Related]  

  • 24. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D
    BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865
    [No Abstract]   [Full Text] [Related]  

  • 25. Ranibizumab for age-related macular degeneration.
    Cheng JW; Wei RL
    N Engl J Med; 2011 Feb; 364(6):582. PubMed ID: 21306263
    [No Abstract]   [Full Text] [Related]  

  • 26. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 27. Study aims to clarify efficacy, safety of eye drug treatments.
    Mitka M
    JAMA; 2007 Apr; 297(14):1538-9. PubMed ID: 17426265
    [No Abstract]   [Full Text] [Related]  

  • 28. Macular degeneration, patients' groups, and pharma.
    The Lancet
    Lancet; 2007 Jul; 370(9583):194. PubMed ID: 17658373
    [No Abstract]   [Full Text] [Related]  

  • 29. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 30. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA; Kim SJ
    Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 33. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC
    Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of exudative age-related macular degeneration: many factors to consider.
    Olsen TW
    Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955
    [No Abstract]   [Full Text] [Related]  

  • 35. A poke in the eye.
    Gurney M
    Nurs Older People; 2007 Dec; 19(10):3. PubMed ID: 18220056
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

  • 37. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 38. Ask the doctor. I have wet macular degeneration. I am trying to decide between Avastin and Lucentis. Which drug is better?
    Heier JS
    Harv Health Lett; 2011 Dec; 37(2):6-7. PubMed ID: 27024308
    [No Abstract]   [Full Text] [Related]  

  • 39. [Avastin-Lucentis: off-label and surroundings].
    Messori A
    Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P; Kankaanpää E
    Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.